(Q30458371)

21 June 2017

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis (English)

1 reference

21 June 2017

0 references

2

David E Jones

1 reference

21 June 2017

Melanie D Ward

1

1 reference

PubMed ID

24935480

21 June 2017

Myla D Goldman

series ordinal

3

1 reference

PubMed ID

24935480

21 June 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

Expert Opinion on Drug Safety

21 June 2017

1 reference

21 June 2017

13

1 reference

21 June 2017

7

1 reference

21 June 2017

989-998

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

21 June 2017

1 reference

Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

The metabolism and function of sphingolipids and glycosphingolipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Impact of sphingosine 1-phosphate modulation on immune outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Distribution of lymphocyte subsets and natural killer cells in the human body

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Clinical pharmacokinetics of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Can PET imaging tell us what's the matter with the gray matter in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Fingolimod-associated macular edema: incidence, detection, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Sudden unexpected death on fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Prolonged and symptomatic bradycardia following a single dose of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Tumefactive MS lesions under fingolimod: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Tumefactive multiple sclerosis lesions under fingolimod treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

21 January 2018

Hemophagocytic syndromes

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Multiple sclerosis and pregnancy: therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.920820

10.1517/14740338.2014.920820

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

24935480